Abstract
Many studies have shown that the third-generation of nonsteroidal aromatase inhibitor has many advantages over clomiphene citrate in ovulation induction. Anastrozole (Arimidex; AstraZeneca, Waltham, MA) is one of these new aromatase inhibitors and, unlike letrozole (Femara; Novartis, East Hanover, NJ), its effectiveness is less well known. It has the similar characteristics with letrozole including a short circulating half-life, well tolerated, relatively inexpensive, and can be orally administered.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
